The KHENERGY Study: Safety and Efficacy of KH176 in Mitochondrial m.3243A>G Spectrum Disorders

KH176 is a potent intracellular reduction–oxidation‐modulating compound developed to treat mitochondrial disease. We studied tolerability, safety, pharmacokinetics, pharmacodynamics, and efficacy of twice daily oral 100 mg KH176 for 28 days in a double‐blind, randomized, placebo‐controlled, two‐way...

Descripción completa

Detalles Bibliográficos
Autores principales: Janssen, Mirian C.H., Koene, Saskia, de Laat, Paul, Hemelaar, Pleun, Pickkers, Peter, Spaans, Edwin, Beukema, Rypko, Beyrath, Julien, Groothuis, Jan, Verhaak, Chris, Smeitink, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704357/
https://www.ncbi.nlm.nih.gov/pubmed/30058726
http://dx.doi.org/10.1002/cpt.1197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704357/
https://www.ncbi.nlm.nih.gov/pubmed/30058726
http://dx.doi.org/10.1002/cpt.1197

Ejemplares similares